TY - JOUR
T1 - Gynecologic cancer intergroup (GCIG) consensus review for uterine serous carcinoma
AU - Sagae, Satoru
AU - Susumu, Nobuyuki
AU - Viswanathan, Akila N.
AU - Aoki, Daisuke
AU - Backes, Floor J.
AU - Provencher, Diane M.
AU - Vaughan, Michelle
AU - Creutzberg, Carien L.
AU - Kurzeder, Christian
AU - Kristensen, Gunnar
AU - Lee, Chulmin
AU - Kurtz, Jean Emmanuel
AU - Glasspool, Rosalind M.
AU - Small, William
PY - 2014/11
Y1 - 2014/11
N2 - Objectives: Uterine serous carcinoma (USC) represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. This article critically reviews the literature pertinent to the epidemiology, pathology, molecular biology, diagnosis, management, and perspectives of patients with USC. Methods: As one of a series of The Gynecologic Cancer InterGroup (GCIG) Rare Tumor Working Group in London, November 2013, we discussed about USC many times with various experts among international GCIG groups. Results: Both USC and approximately 25% of high-grade endometrioid tumors represent extensive copy number alterations, few DNA methylation changes, low estrogen and progesterone levels, and frequent P53mutations. Uterine serous carcinoma shares molecular characteristics with ovarian serous and basal-like breast carcinomas. In addition to optimal surgery, platinum-And taxane-based chemotherapy should be considered in the treatment of both early-And advanced-stage disease. The combination of radiation and chemotherapy appears to be associated with the highest survival rates. The role of radiation therapy in the management of this disease, with a high propensity for distant failures, remains elusive. Conclusions: Uterine serous carcinoma is a unique and biologically aggressive subtype of endometrial cancer and should be studied as a distinct entity. Futures studies should identify the optimized chemotherapy and radiation regimens, sequence of therapy and schedule, and the role of targeted biologic therapy.
AB - Objectives: Uterine serous carcinoma (USC) represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. This article critically reviews the literature pertinent to the epidemiology, pathology, molecular biology, diagnosis, management, and perspectives of patients with USC. Methods: As one of a series of The Gynecologic Cancer InterGroup (GCIG) Rare Tumor Working Group in London, November 2013, we discussed about USC many times with various experts among international GCIG groups. Results: Both USC and approximately 25% of high-grade endometrioid tumors represent extensive copy number alterations, few DNA methylation changes, low estrogen and progesterone levels, and frequent P53mutations. Uterine serous carcinoma shares molecular characteristics with ovarian serous and basal-like breast carcinomas. In addition to optimal surgery, platinum-And taxane-based chemotherapy should be considered in the treatment of both early-And advanced-stage disease. The combination of radiation and chemotherapy appears to be associated with the highest survival rates. The role of radiation therapy in the management of this disease, with a high propensity for distant failures, remains elusive. Conclusions: Uterine serous carcinoma is a unique and biologically aggressive subtype of endometrial cancer and should be studied as a distinct entity. Futures studies should identify the optimized chemotherapy and radiation regimens, sequence of therapy and schedule, and the role of targeted biologic therapy.
KW - GCIG
KW - Review
KW - Uterine serous carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84936082191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84936082191&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000000264
DO - 10.1097/IGC.0000000000000264
M3 - Article
C2 - 25341586
AN - SCOPUS:84936082191
VL - 24
SP - S83-S89
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 9
ER -
